Tesamorelin is an FDA-approved prescription peptide that tells your pituitary gland to make more growth hormone in a natural, pulsatile way. It was approved specifically to reduce dangerous belly fat buildup in HIV patients. Research also suggests it may help with brain function in older adults. Because it raises growth hormone and IGF-1, it requires medical supervision and monitoring.
How it works
Most medicines that raise growth hormone work by putting the hormone straight into your body—like plugging in a space heater that blasts at full power no matter how warm the room already is. Tesamorelin works more like adjusting a thermostat. Instead of forcing heat into the room, it sends a message to the system that controls the heat—the part of your brain in charge of growth hormone. Your body still decides how much to release and when, sends it out in natural waves (mostly while you sleep), and automatically shuts off once you've had enough, just like a thermostat clicking off when the room hits the right temperature. That growth hormone helps your body burn fat—especially the deep belly fat around your organs, which is the harder, more stubborn kind—and can slightly improve your cholesterol. One important note: tesamorelin is FDA-approved for just one specific use (reducing deep belly fat in certain people with HIV), and the fat comes back once the medicine is stopped. Any other use is considered "off-label."
For the nerds:
Tesamorelin is a stabilized analog of growth hormone–releasing hormone (GHRH), modified to resist DPP-4 cleavage so it survives long enough to be therapeutically useful. It binds GHRH receptors on the anterior pituitary and stimulates synthesis and pulsatile release of endogenous GH, preserving the physiologic rhythm and the intact feedback architecture of the GH/IGF-1 axis. This is the key distinction from exogenous rhGH: because you're acting upstream on the secretagogue signal, somatostatin can still brake the system if IGF-1 climbs, providing a physiologic ceiling that direct GH administration bypasses—lowering the risk of a sustained supraphysiologic, insulin-resistant state. Downstream, elevated GH drives lipolysis preferentially in metabolically active visceral adipose tissue, reducing visceral and trunk fat with modest lipid-profile improvements; IGF-1 rises proportionally and remains the monitoring marker. Approved indication is limited to visceral fat reduction in HIV-associated lipodystrophy—evidence is robust there, sparse to anecdotal elsewhere, and the visceral-fat benefit reverses on discontinuation.
What the evidence shows
Overall strength of the evidence, by our read: Strong Evidence. Some of what that rests on:
Tesamorelin reduces visceral adiposity in HIV-infected patients: phase III RCT (2010) — Two pivotal phase III RCTs demonstrated that tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by approximately 15–18% from baseline over 26 weeks versus placebo in HIV lipodystrophy.
Tesamorelin and cognitive function in older adults with mild cognitive impairment: an RCT (2012) — Tesamorelin 1 mg/day for 20 weeks improved executive function and verbal memory scores in older adults with mild cognitive impairment compared to placebo, with IGF-1 elevation correlating with cognitive benefit.
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV (2014) — Tesamorelin significantly reduced liver fat content (measured by MRS) and improved liver enzymes in HIV-infected adults with NAFLD over 12 months.
Preliminary or early findings are not the same as proof. Any use beyond a peptide's FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.
Safety
Injection site reactions, fluid retention, joint pain, muscle aches and pain, and lower extremity swelling are most common. May worsen glucose tolerance and insulin resistance. Contraindicated in active malignancy, pituitary tumor, pregnancy. Potential to increase IGF-1 above normal range with chronic use.
Reasons to avoid it, or to talk to a clinician first:
Active malignancy (FDA contraindication — tesamorelin stimulates GH which can promote tumor growth)
Disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor/surgery (FDA contraindication)
Pregnancy (FDA contraindication — Category X)
Known hypersensitivity to tesamorelin or mannitol (FDA contraindication)
Breastfeeding
This is not a complete safety list.
Questions worth bringing to a clinician
Do I meet criteria for FDA-approved tesamorelin use (HIV-associated lipodystrophy), or would this be off-label?
What are the risks of elevating IGF-1 levels, particularly given any personal or family history of cancer?
How does tesamorelin differ from exogenous growth hormone in terms of safety?
New research, translated
A Two-part Study Investigating the Effect of the X39 Patch on Circulating Blood Levels of GHK and GHK-Cu in a Healthy Adult Population
2027-01 · INTERVENTIONAL · GHK-Cu
Researchers are planning a study of a skin patch called X39, made by LifeWave, to see whether wearing it raises blood levels of two natural copper-peptides—GHK and GHK-Cu—that the body uses for repair. About 100 healthy adults age 35 and older will wear either the real patch or a "dummy" patch, and their blood will be checked on Day 2 and Day 8 to look for any change. The study is sponsored by the patch maker and hasn't started yet, so there are no results to report—it's simply a test of whether the patch does what it claims.
A Phase Ib Clinical Trial, Using Interleukin-2 (IL-2) and Semaglutide in Patients With Alzheimer's Disease
2026-07 · INTERVENTIONAL · semaglutide
Researchers at Houston Methodist are starting a study that pairs semaglutide—the same GLP-1 medicine used for weight loss and diabetes—with a second drug called IL-2 to see if the combination can help people with Alzheimer's disease. The idea is that both drugs calm harmful inflammation in the brain and support the immune "peacekeeper" cells that normally keep that inflammation in check, and early lab work suggests the two work better together than either one alone. This is a small, early safety study of 30 people that is just beginning and won't finish until late 2029, so there are no results yet—it's an early look at whether the combination is safe, not proof that it works.
Oral LNAD+ Rapidly Elevates Intracellular NAD and Metabolic Flux Without Elevating Circulating NAD: Evidence from a Randomized Controlled Trial
biorxiv preprint · 2026-04-27 · NAD+
A new study tested a special oral form of NAD+—a molecule your cells use to make energy that naturally drops as we age—to see whether taking it for five days could raise NAD levels in the body. Interestingly, it raised NAD inside the cells by about 53% compared to a dummy pill, but did not raise NAD floating in the bloodstream, suggesting the body may route it straight into cells where it's actually used, and it was well tolerated with almost no side effects. Keep in mind this was a small, early safety study of 50 healthy adults that hasn't yet been reviewed by outside scientists, and it was funded by the company that makes the product—so it's an early, promising signal, not settled proof.
What readers are asking
Topics we'll be tracking:
New-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching
Real-World Study of Cardiac Remodeling on Semaglutide and Tirzepatide Therapy Using Longitudinal Echocardiography
Off-Trial: Real-World Weight Loss on Tirzepatide and Semaglutide
About Tesamorelin
Tesamorelin (Egrifta, Egrifta SV) is an FDA-approved prescription medication indicated for: HIV-associated lipodystrophy (abdominal fat). Any discussion of uses beyond the FDA-approved labeling is for educational purposes only and does not constitute a recommendation for off-label use. Tesamorelin is a prescription medication that requires a valid prescription from a licensed healthcare provider. Do not attempt to obtain or use this medication without proper medical supervision.
Medical disclaimer
This letter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and no provider-patient relationship is created by reading it. Peptides and medications discussed may not be FDA-approved for the uses described. Always consult your healthcare provider before making any health decision. Read our full medical disclaimer.